The Use of Extended Perioperative Low Molecular Weight Heparin to Improve Cancer Specific Survival Following Surgical Resection of Colon Cancer: A Pilot Randomized Controlled Trial
Cancer patients are at high risk of postoperative thrombosis and this risk remains elevated
beyond the period of hospitalization. Thromboprophylaxis effectively reduces the risk of
post operative VTE in cancer patients. Extended thromboprophylaxis beyond hospitalization
(up to 30 days) with LMWH has been shown to further reduce the risk of postoperative VTE.
Concurrently, there is a growing body of evidence to suggest that LMWH may have anti-cancer
effects due to anti-metastatic properties and may improve survival in cancer patients, even
in the absence of a documented VTE. Retrospective studies have shown that perioperative
thromboprophylaxis (i.e., starting thromboprophylaxis before the surgery) seems to increase
survival in cancer patients undergoing abdominal or pelvic cancer surgery with curative
intent. The investigators propose to perform an open-label RCT to determine if
thromboprophylaxis using tinzaparin 4,500 IU daily, starting from the time of decision to
operate through the peri-operative period and extending for 4 weeks postoperatively, is
feasible.
Interventional
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Recruitment rate
3 months
No
Marc Carrier, MD MSc
Principal Investigator
Ottawa Hospital Research Institute
Canada: Health Canada
2009121-01H
NCT00967148
June 2009
September 2010
Name | Location |
---|